RxDoctor Payments DataLook up a doctor →

Kendal Webb, MD

Hematology & Oncology · Anchorage, AKNPI 1154615250

Payments from drug & device makers

$8,003in general payments, 2019–2025

Across 342 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$980
  • Novartis$588
  • Johnson & Johnson$447
  • E.r. Squibb & Sons, L.L.C.$423
  • Bristol Myers Squibb$367
  • AbbVie$327
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,53294%
  • Education$4726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)39$980
Novartis34$588
Johnson & Johnson(2 entities)19$447
E.r. Squibb & Sons, L.L.C.21$423
Bristol Myers Squibb16$367
AbbVie11$327
Pfizer18$323
Gilead(2 entities)10$276
Seagen Inc.10$269
Incyte Corporation8$254
Exelixis Inc.4$201
Astellas Pharma US Inc8$175
Daiichi Sankyo Inc.4$174
GSK8$167
Rigel Pharmaceuticals, Inc.7$163
Merck6$153
AVEO Pharmaceuticals, Inc.3$144
Sanofi5$142
Pharmacyclics LLC, An Abbvie Company6$142
Genentech USA, Inc.6$139
Amgen6$133
Takeda Pharmaceuticals U.S.A., Inc.5$122
Puma Biotechnology, Inc.5$113
Regeneron Healthcare Solutions, Inc.4$111
Boehringer Ingelheim5$100
Stemline Therapeutics Inc.2$89
Blueprint Medicines Corporation4$84
Array Biopharma Inc4$83
Eisai Inc.4$81
Coherus Oncology, Inc.4$79
EMD Serono, Inc.4$74
Lilly USA, LLC3$64
Servier Pharmaceuticals LLC3$63
Ipsen Biopharmaceuticals, Inc2$52
ADC Therapeutics America, Inc.2$46
Pharmaessentia USA Corporation2$45
Pharmacosmos Therapeutics Inc.2$44
Acrotech Biopharma Inc.2$42
Adaptive Biotechnologies Corporation2$39
Epizyme, Inc.2$38
Dova Pharmaceuticals2$36
Bayer2$35
Jazz Pharmaceuticals Inc.2$35
Kyowa Kirin, Inc.2$35
Legend Biotech USA Inc.1$34
Tersera Therapeutics LLC1$28
Apellis Pharmaceuticals, Inc.1$26
Sanofi-aventis U.S. LLC1$25
G1 Therapeutics, Inc.1$24
Genmab U.S., Inc.1$24
Roche Diagnostics Corporation1$23
Portola Pharmaceuticals, LLC1$23
Morphosys, US Inc.1$22
Beigene USA, Inc.1$22
Spectrum Pharmaceuticals Inc.1$22
Sun Pharmaceutical Industries Inc.1$22
Geron Corporation1$20
Tempus AI, Inc1$20
Heron Therapeutics, Inc.1$19
Taiho Oncology, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,441,648
Medicare patients
363
Services billed
90,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide13$326,718
VerzenioAbemaciclib13$196,618
IbrancePalbociclib12$183,668
XtandiEnzalutamide12$163,271
KisqaliRibociclib Succinate11$147,538
EliquisApixaban36$42,529
Erlotinib Hcl13$4,889
Letrozole70$2,675
Anastrozole30$1,002
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$643
Hydroxyurea20$541
Atorvastatin Calcium14$170
Acyclovir12$138
Alendronate Sodium11$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$367$326,71813 claims
PfizerIbrance, Eliquis$323$226,19748 claims
Lilly USA, LLCVerzenio$64$196,61813 claims
Astellas Pharma US IncXtandi$175$163,27112 claims
NovartisKisqali$588$147,53811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →